相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
Luca Vincenzo Cappelli et al.
LEUKEMIA (2022)
Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia
Robert Puckrin et al.
HAEMATOLOGICA (2021)
Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow
Colin D. Godwin et al.
BLOOD (2021)
Germline mutations in MDS/AML predisposition disorders
Lucy A. Godley
CURRENT OPINION IN HEMATOLOGY (2021)
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia
Charles Craddock et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation
Tanzhen Wang et al.
LEUKEMIA & LYMPHOMA (2021)
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia
Sanam Loghavi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)
Nikhil Patkar et al.
LEUKEMIA (2021)
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial
Catia Simoes et al.
BLOOD ADVANCES (2021)
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Bob Lowenberg et al.
BLOOD ADVANCES (2021)
Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells
Diana Hanekamp et al.
BLOOD (2021)
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations
Roland B. Walter et al.
LEUKEMIA (2021)
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
Ing S. Tiong et al.
BLOOD ADVANCES (2021)
The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively
Mael Heiblig et al.
CANCERS (2021)
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia
Abhishek Maiti et al.
BLOOD ADVANCES (2021)
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
Michael Heuser et al.
BLOOD ADVANCES (2021)
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML
Cheng-Hong Tsai et al.
BLOOD ADVANCES (2021)
Leukemia-associated immunophenotypes subdivided in categories of specificity improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia
Giovanni Rossi et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2020)
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
Richard Dillon et al.
BLOOD (2020)
Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia
Jack Ghannam et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
Christopher S. Hourigan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?
Adriano Venditti et al.
LEUKEMIA (2020)
Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes
Diana Hanekamp et al.
PATHOLOGY (2020)
Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia
Robert P. Hasserjian et al.
BLOOD (2020)
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting
Diana Hanekamp et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting
Katharina M. Lang et al.
TRIALS (2020)
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial
Silke Kapp-Schwoerer et al.
BLOOD (2020)
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia A Systematic Review and Meta-analysis
Nicholas J. Short et al.
JAMA ONCOLOGY (2020)
The Natural History of NPM1MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)
Ing Soo Tiong et al.
BLOOD (2020)
Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia
Laura W. Dillon et al.
HAEMATOLOGICA (2019)
Pre-analytical processes in medical diagnostics: New regulatory requirements and standards
Georges Dagher et al.
NEW BIOTECHNOLOGY (2019)
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Sibylle Cocciardi et al.
NATURE COMMUNICATIONS (2019)
Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients
Marta Santaliestra et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
Adriano Venditti et al.
BLOOD (2019)
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
Frank G. Ruecker et al.
BLOOD (2019)
Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes
Anna Elinder Camburn et al.
PATHOLOGY (2019)
Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)
Veit Bucklein et al.
BLOOD (2019)
An R-Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry Data
Francis Lacombe et al.
CYTOMETRY PART A (2019)
Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing
Vidya Balagopal et al.
PLOS ONE (2019)
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT
Christoph Schmid et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia
Wendelien Zeijlemaker et al.
LEUKEMIA (2019)
Minimal residual disease and stem cell transplantation outcomes
Jacqueline Cloos et al.
Hematology-American Society of Hematology Education Program (2019)
Innovation in Flow Cytometry Analysis: A New Paradigm Delineating Normal or Diseased Bone Marrow Subsets Through Machine Learning
Francis Lacombe et al.
HEMASPHERE (2019)
Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia
Francis Lacombe et al.
HEMATOLOGICAL ONCOLOGY (2018)
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation
Maria H. Gilleece et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)
Takaaki Konuma et al.
ANNALS OF HEMATOLOGY (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies
Robert L. Bowman et al.
CELL STEM CELL (2018)
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 3-data analysis, reporting and case studies
Andrea Illingworth et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2018)
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
Felicitas Thol et al.
BLOOD (2018)
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Uwe Platzbecker et al.
LANCET ONCOLOGY (2018)
NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse
Alexander Hoellein et al.
BLOOD ADVANCES (2018)
Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients
Diana Hanekamp et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse
TaeHyung Kim et al.
BLOOD (2018)
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations
Mark J. Levis et al.
BLOOD ADVANCES (2018)
Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry
Sergio Matarraz et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2017)
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab
Yasmin Abaza et al.
BLOOD (2017)
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group
Marie Balsat et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML
S. Herold et al.
LEUKEMIA (2017)
Measurable residual disease testing in acute myeloid leukaemia
C. S. Hourigan et al.
LEUKEMIA (2017)
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
J. Flores-Montero et al.
LEUKEMIA (2017)
High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia
Adriana Plesa et al.
WORLD JOURNAL OF STEM CELLS (2017)
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
Bob Lowenberg et al.
BLOOD (2017)
Harmonemia: a universal strategy for flow cytometry immunophenotyping-A European LeukemiaNet WP10 study
F. Lacombe et al.
LEUKEMIA (2016)
Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia
Y. Zhou et al.
LEUKEMIA (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia
Thomas Prebet et al.
HAEMATOLOGICA (2014)
Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
Monique Terwijn et al.
PLOS ONE (2014)
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
Juliette Lambert et al.
ONCOTARGET (2014)
The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML
Nona Shayegi et al.
BLOOD (2013)
Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS - Part I - Rationale and Aims
Bruce H. Davis et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)
Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS - Part V - Assay Performance Criteria
Brent Wood et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)
Technical issues: flow cytometry and rare event analysis
B. D. Hedley et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2013)
Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
J. J. M. van Dongen et al.
LEUKEMIA (2012)
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
Francesco Lo-Coco et al.
BLOOD (2010)
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
Daniela Cilloni et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia
F. Buccisano et al.
LEUKEMIA (2006)
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy:: a multicenter study by the PETHEMA group
MA Sanz et al.
BLOOD (2004)
分享论文
